These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 30151414)

  • 1. Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection.
    Serota DP; Franch HA; Cartwright EJ
    Open Forum Infect Dis; 2018 Aug; 5(8):ofy189. PubMed ID: 30151414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
    Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
    Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
    Michal JL; Rab S; Patel M; Kyle AW; Miller LS; Easley KA; Kalapila AG
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):690-698. PubMed ID: 29766745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.
    Buti M; Riveiro-Barciela M; Esteban R
    J Infect Dis; 2017 Nov; 216(suppl_8):S792-S796. PubMed ID: 29156043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Epi-TAF for Tenofovir Disoproxil Fumarate?
    Walensky RP; Horn TH; Paltiel AD
    Clin Infect Dis; 2016 Apr; 62(7):915-8. PubMed ID: 26658300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient.
    Mothobi NZ; Masters J; Marriott DJ
    Ther Adv Infect Dis; 2018 Sep; 5(5):91-95. PubMed ID: 30224952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
    Margot NA; Liu Y; Miller MD; Callebaut C
    Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity.
    Walti LN; Steinrücken J; Rauch A; Wandeler G
    Open Forum Infect Dis; 2018 Nov; 5(11):ofy275. PubMed ID: 30515426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
    MacBrayne CE; Marks KM; Fierer DS; Naggie S; Chung RT; Hughes MD; Kim AY; Peters MG; Brainard DM; Seifert SM; Castillo-Mancilla JR; Bushman LR; Anderson PL; Kiser JJ
    J Antimicrob Chemother; 2018 Aug; 73(8):2112-2119. PubMed ID: 29746648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
    Cevik M; Orkin C
    Curr Opin HIV AIDS; 2018 Jul; 13(4):315-319. PubMed ID: 29528852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    J Clin Virol; 2018 Jun; 103():37-42. PubMed ID: 29627709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incident hepatocellular carcinoma developing during tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis B virus infection: A case report and review of the literature.
    Lu JC; Liu LG; Lin L; Zheng SQ; Xue Y
    World J Clin Cases; 2018 Nov; 6(13):671-674. PubMed ID: 30430123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
    Angione SA; Cherian SM; Özdener AE
    J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV-HCV Coinfection.
    Doyle MA; Lee T; Singer J; Crawley A; Klein M; Cooper C
    Open Forum Infect Dis; 2019 Jul; 6(7):. PubMed ID: 31363776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate.
    Golla VM; Kurmi M; Shaik K; Singh S
    J Pharm Biomed Anal; 2016 Nov; 131():146-155. PubMed ID: 27589032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence.
    Byrne R; Carey I; Agarwal K
    Therap Adv Gastroenterol; 2018; 11():1756284818786108. PubMed ID: 30034532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
    Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
    HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
    Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
    Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.